RAPT Therapeutics, Inc. (RAPT)

Rapt Therapeutics' stock has experienced significant movements, with a 52-week range between $5.67 and $42.39. A 1-for-8 reverse stock split was effected on June 16, 2025. Positive topline data from a Phase 2 trial of ozureprubart (RPT904) in chronic spontaneous urticaria was announced in October 2025, and a Phase 2b clinical trial for ozureprubart in IgE-mediated food allergy was initiated. An October 2025 public offering secured approximately $234.4 million. Rapt Therapeutics reported a net loss of ($0.65) earnings per share for Q3 2025. Analyst firms initiated coverage, upgraded ratings, or increased price targets for RAPT, contributing to a "Moderate Buy" consensus rating. Earlier in April 2025, the stock hit a 52-week low of $0.78, and the company received a Nasdaq minimum bid price deficiency notice in May 2025.

As a clinical-stage biopharmaceutical company, Rapt Therapeutics, Inc. currently has no commercial product revenue and therefore no direct demand seasonality. Its economic value is tied to the potential future commercial success of its drug candidates.

Rapt Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on developing oral small-molecule therapies for oncology and inflammatory diseases. Their pipeline includes Tivumecirnon (FLX475) for oncology and Ozureprubart (RPT904) for inflammatory reactions. The zelnecirnon program was discontinued in November 2024 after a clinical hold by the FDA.

Rapt Therapeutics, Inc. is headquartered in South San Francisco, California. Clinical trials for ozureprubart (RPT904) are being conducted across 30 sites in the U.S., Canada, and Australia.

Rapt Therapeutics' brand reputation has been impacted by both setbacks and promising developments. The FDA placed a clinical hold on zelnecirnon, leading to its discontinuation and workforce reductions. Positive clinical trial results for ozureprubart (RPT904) and analyst upgrades have contributed to a recovering reputation.

Rapt Therapeutics, Inc. is primarily controlled by institutional investors. Approximately 31.9% is held by institutions, 28.2% by VC/PE Firms, 5.31% by Hedge Funds, 0.253% by individual insiders, and 34.3% by the general public. Major institutional and individual owners include TCG Crossover Management, LLC, Foresite Capital Management VI LLC, and Rtw Investments, Lp.